



Please Note: Medical Necessity Prior Authorization may be overridden for both formulary coverage and benefit design restrictions. They are issued at the full discretion of the benefit manager.

PRIOR AUTHORIZATION **BYPASS**

Onglyza® (saxagliptin)

Bypass the Prior Authorization by Modifying the following Prescription Forms to the Patient's Needs

Name _____
 Address _____

R_x

MD _____
 Signature _____

Name _____
 Address _____

**R_x COMPLETE
 PRIOR
 AUTHORIZATION
 FORMS**

as directed by physician

**Dx: DIABETES
 ICD 10: E 13.9**

MD _____
 Signature _____

SAMPLE



Prescriber Information

Last Name: <input type="text"/> DEA/NPI: <input type="text"/> Phone <input type="text"/>	First Name <input type="text"/> Specialty: <input type="text"/> Fax <input type="text"/>
--	--

Member Information

Last Name: <input type="text"/> Member ID Number <input type="text"/>	First Name <input type="text"/> DOB: <input type="text"/>
--	--

Medication Information:

Drug Name and Strength: <input type="text"/> Diagnosis: <input type="text"/>	Quantity and Dosing: <input type="text"/> Duration: <input type="text"/>
---	---

When advised below, please include all requested fax documentation (lab results, etc.) when submitting this Prior Authorization fax form; not submitting requested documentation could delay the clinical review process.

**Januvia, Janumet, Janumet XR, Jentadueto, Kazano, Kombiglyze XR, Nesina, Onglyza, Oseni, & Tradjenta
Prior Authorization Form**

You must answer ALL of the following questions		
1. Is the patient 18 years of age or older?	Y	N
2. Does the patient have one of the following diagnoses? (Please Circle) <ul style="list-style-type: none"> • Type 2 diabetes • Type 1 diabetes 	Y	N
3. Has the patient previously been on this therapy?	Y	N
4. Is the patient's HbA1c greater than 6.9%? <i>HbA1c must be taken within the past 6 months. Please provide documentation.</i>	Y	N
5. Was the patient's HbA1c greater than 6.9% prior to starting therapy? <i>Please provide documentation.</i>	Y	N
6. Is the patient currently taking OR has the patient had an inadequate response, intolerance, or contraindication to metformin? <i>Please provide documentation.</i>	Y	N
7. Is the patient currently taking OR has the patient had an inadequate response, intolerance, or contraindication to a sulfonylurea or a thiazolidinedione (e.g., Actos, Avandia)? <i>Please provide documentation.</i>	Y	N



<p>8. Is the patient currently taking any of the following medications? (Please Circle)</p> <ul style="list-style-type: none"> • Precose (acarbose) • Byetta, Bydureon (exenatide) • Invokana (canagliflozin) • Jardiance (empagliflozin) • Tanzeum (albiglutide) • Trulicity (dulaglutide) • Glyset (miglitol) • Victoza (liraglutide) • Invokamet (canagliflozin/metformin) • Farxiga (dapagliflozin) • Xigduo XR (dapagliflozin/metformin) • Any other DPP4 inhibitor product (including combination products) 	Y	N
<p>9. If the patient is taking any of the following medications, will concomitant therapy with those agents be discontinued? (Please Circle)</p> <ul style="list-style-type: none"> • Precose (acarbose) • Byetta, Bydureon (exenatide) • Invokana (canagliflozin) • Jardiance (empagliflozin) • Tanzeum (albiglutide) • Trulicity (dulaglutide) • Glyset (miglitol) • Victoza (liraglutide) • Invokamet (canagliflozin/metformin) • Farxiga (dapagliflozin) • Xigduo XR (dapagliflozin/metformin) • Any other DPP4 inhibitor product (including combination products) 	Y	N

Please note, not all drugs/diagnoses are covered on all plans.

Comments: _____
Information given on this form is accurate as of this date.

Prior Authorization forms are located on the Cover Page. Print a new form for each request as forms are updated periodically.

Prescriber or Authorized Signature

Date

Authorized Medical Staff – Name/Title

Attention Healthcare Provider: If you would like to discuss this request with a medical professional, please contact the Prior Authorization Department whose numbers appear on the Cover Page.

I understand that US Doctor's use or disclosure of individually identifiable health information, whether furnished by me or obtained by another source such as medical providers, shall be in accordance with federal privacy regulations under HIPAA (Health Insurance Portability and Accountability Act of 1996).



Contact Information:

Telephone: (855)251.9116

Fax: (248)593.9575

Please Note: Medical Necessity Prior Authorization may be utilized to override both formulary coverage and benefit design restrictions. They are issued at the full discretion of the benefit manager.

**PRIOR AUTHORIZATION FORM:
COVER PAGE**

MEMBER INFORMATION			
First Name		Last Name	
Plan			
Member ID		Date of Birth	
DRUG INFORMATION			
Drug Name			
Quantity		ICD-10	
Directions		Duration of Therapy	
Diagnosis			
PLEASE LIST ALTERNATIVE THERAPIES THAT HAVE BEEN ATTEMPTED AND ANY OTHER PERTINENT INFORMATION RELATED TO DRUG AND/OR DISEASE STATE. IF NOT PRESENT, WITHIN NORMAL LIMITS WILL BE USED FOR THE REVIEW.			
Medication/Failure Reason:			
IgE: _____ ESR: _____ CRP: _____ # Joints: _____ %BSA: _____ Height: _____ Weight: _____ BMI: _____ HA1C: _____ Hemoglobin: _____ Hematocrit: _____ T-Score: _____ Dialysis: _____ Long Term Care Facility: _____ Self Injecting: _____ Stimulation test: _____ / _____ Growth velocity: _____ #Chemotherapy cycles/month: _____ Mini-Mental Status Test: _____ Baseline Free testosterone/Total testosterone: _____ / _____ HCV RNA viral load: _____ Viral Genotype: _____ ALT: _____			
PHYSICIAN INFORMATION			
Physician Signature		Date	
Physician Name		NPI #	
Phone Number		Fax Number	
Action Needed	Only mark Urgent when standard review time would seriously harm the member's life or health or ability to regain maximum function <input type="checkbox"/> Urgent <input type="checkbox"/> For Review	Pharmacy Fax	
The information contained in this facsimile message, including the attachments, may be privileged, may constitute inside information and is intended only for use of the addressee. If the reader of this message is not the intended recipient, or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited and may be unlawful. If you have received this communication in error, please immediately notify me by replying to this message and destroy the original message.			